NASDAQ:GBIO - Generation Bio Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $19.33
  • Forecasted Upside: 148.50 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$7.78
▲ +0.17 (2.23%)

This chart shows the closing price for GBIO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Generation Bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GBIO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GBIO

Analyst Price Target is $19.33
▲ +148.50% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Generation Bio in the last 3 months. The average price target is $19.33, with a high forecast of $24.00 and a low forecast of $11.00. The average price target represents a 148.50% upside from the last price of $7.78.

This chart shows the closing price for GBIO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 investment analysts is to buy stock in Generation Bio. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/15/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/16/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/14/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/12/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/10/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/11/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/10/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/9/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/8/2022JMP SecuritiesBoost Price TargetMarket Outperform$10.00 ➝ $11.00Low
8/5/2022WedbushReiterated RatingOutperform$24.00Low
8/5/2022Needham & Company LLCLower Price TargetBuy$27.00 ➝ $23.00Low
4/12/2022Needham & Company LLCReiterated RatingBuy$27.00Medium
12/15/2021Needham & Company LLCLower Price TargetBuy$50.00 ➝ $27.00High
12/15/2021JMP SecuritiesLower Price TargetMarket Outperform$40.00 ➝ $10.00High
12/15/2021JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralHigh
12/14/2021William BlairDowngradeOutperform ➝ Market PerformHigh
6/8/2021JMP SecuritiesInitiated CoverageOutperform$40.00Medium
3/22/2021JPMorgan Chase & Co.Boost Price TargetOverweight$34.00 ➝ $39.00Medium
2/23/2021William BlairInitiated CoverageOutperform$45.00High
2/18/2021Needham & Company LLCInitiated CoverageBuy$50.00Medium
7/7/2020JPMorgan Chase & Co.Initiated CoverageOverweight$28.00Medium
7/7/2020WedbushInitiated CoverageOutperform$31.00Medium
7/7/2020CowenInitiated CoverageOutperformMedium
7/7/2020Jefferies Financial GroupInitiated CoverageBuy$38.00Medium
(Data available from 8/10/2017 forward)

News Sentiment Rating

-0.03 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
1/12/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/11/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/13/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/12/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
5/12/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/11/2022
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/11/2022
  • 0 very positive mentions
  • 8 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
8/10/2022

Current Sentiment

  • 0 very positive mentions
  • 8 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Generation Bio logo
Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $7.78
Low: $7.69
High: $7.78

50 Day Range

MA: $6.63
Low: $5.19
High: $8.11

52 Week Range

Now: $7.78
Low: $3.96
High: $28.67

Volume

97 shs

Average Volume

433,260 shs

Market Capitalization

$459.11 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.89

Frequently Asked Questions

What sell-side analysts currently cover shares of Generation Bio?

The following equities research analysts have issued reports on Generation Bio in the last twelve months: JMP Securities, JPMorgan Chase & Co., Needham & Company LLC, Wedbush, and William Blair.
View the latest analyst ratings for GBIO.

What is the current price target for Generation Bio?

3 Wall Street analysts have set twelve-month price targets for Generation Bio in the last year. Their average twelve-month price target is $19.33, suggesting a possible upside of 148.5%. Wedbush has the highest price target set, predicting GBIO will reach $24.00 in the next twelve months. JMP Securities has the lowest price target set, forecasting a price of $11.00 for Generation Bio in the next year.
View the latest price targets for GBIO.

What is the current consensus analyst rating for Generation Bio?

Generation Bio currently has 2 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GBIO will outperform the market and that investors should add to their positions of Generation Bio.
View the latest ratings for GBIO.

What other companies compete with Generation Bio?

How do I contact Generation Bio's investor relations team?

Generation Bio's physical mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The company's listed phone number is 617-655-7500 and its investor relations email address is [email protected] The official website for Generation Bio is generationbio.com. Learn More about contacing Generation Bio investor relations.